A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

March 17, 2026 updated by: Syndax Pharmaceuticals

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.

In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Phase 1: Oral revumenib; sequential cohorts of escalating dose levels of revumenib to identify the MTD and RP2D. Participants will be enrolled in one of six dose-escalation arms:

Arm A: Participants not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducers or fluconazole.

Arm B: Participants receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis.

Arm C: Participants receiving revumenib and cobicistat.

Arm D: Participants receiving fluconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis.

Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers.

Arm F: Participants receiving isavuconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis.

In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib:

  • Cohort 2A: Participants with KMT2Ar acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL)
  • Cohort 2B: Participants with KMT2A AML
  • Cohort 2C: Participants with NPM1m AML
  • Cohort 2D: Participants with acute leukemia (including KMT2Ar, NPM1m, NUP98r and other acute leukemias expected to have HOX/MEIS upregulation)

Study Type

Interventional

Enrollment (Estimated)

447

Phase

  • Phase 2
  • Phase 1

Expanded Access

No longer available outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Australia
      • Melbourne, Australia, 3004
        • Recruiting
        • Alfred Hospital
        • Principal Investigator:
          • Shaun Fleming, MD
      • Nedlands, Australia, 6009
        • Recruiting
        • Sir Charles Gairdner Hospital
        • Principal Investigator:
          • Carolyn Grove, MD
      • Saint Leonards, Australia, 2065
        • Recruiting
        • Royal North Shore Hospital
        • Principal Investigator:
          • Matthew Greenwood, MD
    • Victoria
      • Melbourne, Victoria, Australia, 3000
        • Active, not recruiting
        • Peter MacCallum Cancer Centre (PMCC)
      • Parkville, Victoria, Australia, 3050
        • Active, not recruiting
        • Royal Melbourne Hospital (RMH)
  • Canada
      • Toronto, Canada, M5G 2M9
        • Recruiting
        • University Health Network
        • Principal Investigator:
          • Andre Schuh, MD
        • Contact:
      • Toronto, Canada
        • Active, not recruiting
        • The Hospital for Sick Children
  • France
      • Paris, France, 75010
        • Recruiting
        • Hospital Saint-Louis - APHP
        • Principal Investigator:
          • Emmanuel Raffoux
        • Contact:
      • Pessac, France, 33604
        • Recruiting
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
        • Principal Investigator:
          • Arnaud Pigneux
        • Contact:
      • Pierre-Bénite, France, 69495
      • Villejuif, France, 94805
        • Recruiting
        • Institut Gustave Roussy-Gustave Roussy Cancer Center -Ditep
        • Contact:
        • Principal Investigator:
          • Stephanie De Botton
  • Germany
      • Essen, Germany, 45147
        • Withdrawn
        • Universitaetsklinikum Essen (AoR)
      • Greifswald, Germany, 17475
        • Completed
        • Universitaetsmedizin Greifswald
      • Gutenberg, Germany, 55131
      • Hamburg, Germany, 20246
        • Recruiting
        • Universitaetsklinikum Hamburg-Eppendorf
        • Contact:
        • Principal Investigator:
          • Franziska Westendorf
      • Leipzig, Germany, 04103
      • Nuremberg, Germany, 90419
        • Completed
        • Klinikum Nuernberg Nord
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Germany, 89081
        • Recruiting
        • University Hospital Of Ulm, Universitatsklinikum Ulm
        • Principal Investigator:
          • Hartmut Doehner
        • Contact:
  • Israel
      • Haifa, Israel, 3109601
        • Recruiting
        • Rambam Health Care Campus (RHCC)
        • Principal Investigator:
          • Avraham Frisch
        • Contact:
      • Jerusalem, Israel, 9103102
        • Recruiting
        • Shaare Zedek Medical Center
        • Principal Investigator:
          • Yishai Ofran
        • Contact:
      • Jerusalem, Israel, 9112001
        • Recruiting
        • Hadassah Medical Center- Ein Kerem
        • Principal Investigator:
          • Boaz Nachmias
        • Contact:
          • Leah Greenfeld
        • Contact:
      • Nahariya, Israel, 2210010
        • Recruiting
        • Galilee Medical Center
        • Contact:
        • Principal Investigator:
          • Galia Stemer
      • Petah Tikva, Israel, 4941492
        • Recruiting
        • Rabin Medical Center
        • Principal Investigator:
          • Ofir Wolach
        • Contact:
      • Ramat Gan, Israel, 52621
  • Italy
      • Bologna, Italy, 40138
        • Recruiting
        • IRCCS Azienda Ospedaliero Universitaria di Bologna
        • Principal Investigator:
          • Cristina Papayannidis
        • Contact:
      • Meldola, Italy, 47014
        • Recruiting
        • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
        • Contact:
        • Principal Investigator:
          • Irene Zacheo
      • Milan, Italy, 20141
        • Recruiting
        • IRCCS-Istituto Europeo di Oncologia
        • Principal Investigator:
          • Enrico Derenzini
        • Contact:
      • Roma, Italy, 00168
        • Recruiting
        • Universita Cattolica Fondazione Policlinico Agostino Gemelli
        • Principal Investigator:
          • Patrizia Chiusolo
        • Contact:
      • Vicenza, Italy, 36100
  • Lithuania
      • Vilnius, Lithuania, 08661
        • Recruiting
        • Vilnius University Hospital Santaros Klinikos
        • Principal Investigator:
          • Andrius Zucenka
        • Contact:
  • Netherlands
      • Utrecht, Netherlands, 3584 CS
        • Recruiting
        • Princess Máxima Center for Pediatric Oncology
        • Contact:
        • Principal Investigator:
          • Michael Zwaan
  • Puerto Rico
      • San Juan, Puerto Rico, 00935
        • Recruiting
        • Hospital Centro Comprensivo de Cancer UPR
        • Principal Investigator:
          • Alexis Cruz-Chacon
        • Contact:
  • Spain
      • L'Hospitalet de Llobregat, Spain, 08908
        • Recruiting
        • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
        • Principal Investigator:
          • Montserrat Arnan Sangerman
        • Contact:
      • Seville, Spain, 41013
        • Recruiting
        • Hospital Universitario Virgen del Rocio
        • Contact:
        • Principal Investigator:
          • Eduardo Rodriguez-Arboli
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitari i Politecnic La Fe de Valencia
        • Principal Investigator:
          • Pau Montesinos Fernandez
        • Contact:
  • United States
    • California
      • Duarte, California, United States, 91010
        • Active, not recruiting
        • City of Hope Comprehensive Cancer Center
      • Los Angeles, California, United States, 90033
        • Completed
        • University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital
      • Palo Alto, California, United States, 94305
        • Active, not recruiting
        • Stanford Cancer Institute
    • Colorado
      • Aurora, Colorado, United States, 80045
    • Florida
      • Sarasota, Florida, United States, 34232
        • Active, not recruiting
        • Florida Cancer Specialists and Research Institute
      • Tampa, Florida, United States, 33162
        • Completed
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Emory Winship Cancer Institute
        • Principal Investigator:
          • Martha Arellano
        • Contact:
      • Atlanta, Georgia, United States, 30329
        • Completed
        • Children's Healthcare of Atlanta
    • Illinois
    • Iowa
      • Iowa City, Iowa, United States, 52246
        • Recruiting
        • University of Iowa Hospital
        • Principal Investigator:
          • David Dickens, MD
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Active, not recruiting
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University in St. Louis School of Medicine
        • Principal Investigator:
          • John DiPersio
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Completed
        • Hackensack University Medical Center
    • New York
      • New York, New York, United States, 10065
        • Active, not recruiting
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, United States, 10467
    • North Carolina
      • Durham, North Carolina, United States, 27110
        • Recruiting
        • Duke University Medical Center
        • Contact:
        • Principal Investigator:
          • Brittany DePriest
    • Ohio
      • Cincinnati, Ohio, United States, 45267
        • Completed
        • University of Cincinnati
      • Columbus, Ohio, United States, 43201
        • Recruiting
        • Ohio State University
        • Contact:
        • Principal Investigator:
          • James Blachly
    • Oregon
      • Portland, Oregon, United States, 97239
        • Recruiting
        • Oregon Health & Science University
        • Principal Investigator:
          • Elie Traer, MD
        • Contact:
    • Pennsylvania
    • Texas
      • Houston, Texas, United States, 77030
        • Active, not recruiting
        • The University of Texas MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Completed
        • Huntsman Cancer Institute at the University of Utah

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 weeks and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

Participants must have active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020), or acute leukemia harboring KMT2A rearrangement, NUP98 rearrangement, or NPM1 mutation that have detectable disease in the bone marrow.

  1. Phase 1:

    • Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole.
    • Arm B: Participants receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis.
    • Arm C: Participants receiving revumenib in combination with cobicistat.
    • Arm D: Participants receiving fluconazole (moderate CYP3A4 inhibitor).
    • Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers.
    • Arm F: Participants receiving isavuconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis.

  2. Phase 2:

    Documented R/R active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the NCCN Guidelines® for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020).

    • Cohort 2A: Documented R/R ALL/MPAL with KMT2A rearrangement.
    • Cohort 2B: Documented R/R AML with KMT2A rearrangement.
    • Cohort 2C: Documented R/R AML with NPM1m.
    • Cohort 2D: Documented R/R acute leukemia with a genetic mutation expected to lead to HOX/MEIS upregulation (for example, KMT2Ar, NPM1m, and NUP98r), including participants who are MRD-positive by multiparametric flow cytometry or molecular methods only, and including participants with isolated extramedullary disease.
  3. White blood cell count below 25,000/ microliter at time of enrollment. Participants may receive cytoreduction prior to enrollment per protocol-specified criteria.
  4. Male or female participants aged ≥30 days old. Participants intended to receive SNDX-5613 in combination with cobicistat must weigh ≥35 kilograms (kg). Participants in Cohort 2D must be ≥18 years of age and have a body weight ≥40 kg.
  5. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 or Karnofsky/Lansky score ≥50.

  6. Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with the exception of ≤Grade 2 neuropathy or alopecia.

    Phase 1 and Phase 2 Cohorts 2A-2C only:

  7. Radiation Therapy: At least 60 days from prior total body irradiation (TBI), craniospinal radiation and/or ≥50% radiation of the pelvis, or at least 14 days from local palliative radiation therapy (small port).
  8. Stem Cell Infusion: At least 60 days must have elapsed from hematopoietic stem cell transplant and at least 4 weeks must have elapsed from donor lymphocyte infusion.
  9. Immunotherapy: At least 42 days since prior immunotherapy, including tumor vaccines, and at least 21 days since receipt of chimeric antigen receptor therapy or other modified T or NK cell therapy.
  10. Antileukemia Therapy: At least 14 days, or 5 half-lives, whichever is shorter, since the completion of antileukemic therapy.
  11. Hematopoietic Growth Factors: At least 7 days since the completion of therapy with short-acting hematopoietic growth factors and 14 days with long-acting growth factors.
  12. Biologics: At least 90 days, or 5 half-lives, whichever is shorter, since the completion of therapy with an antineoplastic biologic agent.

  13. Steroids: At least 7 days since systemic glucocorticoid therapy, unless receiving physiologic dosing or cytoreductive therapy.

    Phase 2 Cohort 2D only:

    At least 14 days since any other investigational or commercially available antileukemic therapy, with the following exceptions:

    1. Cytoreductive therapy with hydroxyurea, low-dose cytarabine (20 mg/square meter (m^2)/day subcutaneously [SC] for 10 days) or low-dose etoposide (up to 200 mg/day orally for 10 days) may be administered concurrently with SNDX-5613.
    2. Intrathecal chemotherapy for CNS prophylaxis is permitted at the treating physician's discretion.
    3. Steroids at physiologic dosing (equivalent to ≤10 mg prednisone daily for participants ≥18 years or ≤10 mg/m^2/day for participants <18 years) or for cytoreductive therapy.
  14. Adequate organ function.
  15. If of childbearing potential, willing to use a highly effective method of contraception from the time of enrollment through 120 days following the last study drug dose.

Key Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for study participation:

  1. Diagnosis of active acute promyelocytic leukemia.
  2. Isolated extramedullary relapse (Phase 2 Cohorts 2A-2C only).
  3. Active central nervous system disease (cytologic, such as any blasts on cytospin, or radiographic).
  4. Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Participants with a known history of HIV 1/2 antibodies must have viral load testing prior to study enrollment.
  5. Hepatitis B or C.
  6. Pregnant or nursing women.

  7. Cardiac Disease:

    • Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
    • Corrected QT interval (QTc) >450 milliseconds.

  8. Gastrointestinal Disease:

    • any gastrointestinal issue of the upper GI tract that might affect oral drug absorption or ingestion (that is, gastric bypass and gastroparesis).
    • Cirrhosis with a Child-Pugh score of B or C.
  9. Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD >Grade 0 within 4 weeks of enrollment. All transplant participants must have been off all systemic immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to enrollment. Participants may be on physiological doses of steroids.
  10. Concurrent malignancy in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (for example, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy, or concurrent low-grade lymphoma, that is asymptomatic and lacks bulky disease and shows no evidence of progression, and for which the participant is not receiving any systemic therapy or radiation.
  11. In Phase 1 and Phase 2: Participants requiring the concurrent use of medications known or suspected to prolong the QT/QTc interval, with the exception of drugs with low risk of QT/QTc prolongation that are used as standard supportive therapies (for example, diphenhydramine, famotidine, ondansetron, Bactrim) and the azoles permitted in the relevant arms of Phase 1 and in Phase 2.

Note: Other protocol defined inclusion/exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Revumenib

Phase 1: Oral revumenib; sequential cohorts of escalating dose levels of revumenib. Participants will be enrolled in 1 of 6 dose-escalation arms:

  • Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole
  • Arm B: Participants receiving any strong CYP3A4 inhibitors for antifungal prophylaxis
  • Arm C: Participants receiving revumenib and cobicistat
  • Arm D: Participants receiving fluconazole for antifungal prophylaxis
  • Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers
  • Arm F: Participants receiving isavuconazole for antifungal prophylaxis

Phase 2: Oral revumenib; 4 indication-specific expansion cohorts will be enrolled:

  • Cohort 2A: Participants with KMT2Ar ALL/MPAL
  • Cohort 2B: Participants with KMT2Ar AML
  • Cohort 2C: Participants with NPM1m AML
  • Cohort 2D: Participants with acute leukemia (including KMT2Ar, NPM1m, NUP98r and other acute leukemias expected to have HOX/MEIS upregulation)
Drug: cobicistat
Phase 1 Arm C participants will receive 150 mg cobicistat daily.
Drug: revumenib
revumenib orally
Other Names:
  • SNDX-5613

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with treatment-emergent adverse events (TEAEs) (Phase 1)
Time Frame: Approximately 1 year
Assessed by the NCI CTCAE version 5.0 (Phase 1)
Approximately 1 year
Cmax (Phase 1)
Time Frame: Approximately 1 year
Maximum plasma concentration (Cmax) of revumenib and relevant metabolites (Phase 1)
Approximately 1 year
Tmax (Phase 1)
Time Frame: Approximately 1 year
Time to observed maximum plasma concentration of revumenib and relevant metabolites (Phase 1)
Approximately 1 year
AUC0-t (Phase 1)
Time Frame: Approximately 1 year
Area under the plasma concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of revumenib and relevant metabolites (Phase 1)
Approximately 1 year
Number of participants with dose-limiting toxicities (DLTs) (Phase 1)
Time Frame: Approximately 1 year
Assessed by the NCI CTCAE version 5.0 (Phase 1)
Approximately 1 year
CR+CRh rate (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
To assess the complete remission (CR) and complete remission with partial hematologic recovery (CRh) rate (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
Number of participants with TEAEs (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
Assessed by the NCI CTCAE version 5.0 (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
Cmax (Phase 2 [Cohort 2D])
Time Frame: Approximately 3 years
Cmax of revumenib (Phase 2 [Cohort 2D])
Approximately 3 years
AUC0-tau (Phase 2 [Cohort 2D])
Time Frame: Approximately 3 years
Area under the plasma concentration-time curve from time 0 to the end of the dosing interval (AUC0-tau) of revumenib (Phase 2 [Cohort 2D])
Approximately 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Transfusion independence (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
Transfusion independence is defined as any transfusion-free period lasting for at least 56 consecutive days
Approximately 3 years
CRc rate (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
To assess the composite definition of complete remission (CRc) rate (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
ORR (CRc+ morphological leukemia-free state [MLFS] + partial remission [PR]) (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
To assess the overall response rate (ORR) of revumenib (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
TTR (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 34 months
To assess the time to response (TTR) of revumenib (Phase 2 [Cohorts 2A-2C])
Approximately 34 months
DOR (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
To assess the duration of response (DOR) of revumenib (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
EFS (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
To assess the event free survival (EFS) of revumenib (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
OS (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 5 years
To assess overall survival (OS) of revumenib (Phase 2 [Cohorts 2A-2C])
Approximately 5 years
Cmax (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
Cmax of revumenib and relevant metabolites (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
Tmax (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
Tmax of revumenib and relevant metabolites (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
AUC0-t (Phase 2 [Cohorts 2A-2C])
Time Frame: Approximately 3 years
AUC0-t of revumenib and relevant metabolites (Phase 2 [Cohorts 2A-2C])
Approximately 3 years
Number of participants with TEAEs (Phase 2 [Cohort 2D])
Time Frame: Approximately 3 years
Assessed by the NCI CTCAE version 5.0 (Phase 2 [Cohort 2D]))
Approximately 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Syndax Pharmaceuticals

Investigators

  • Study Director: Angela R Smith, M.D., Syndax Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2019

Primary Completion (Estimated)

December 15, 2027

Study Completion (Estimated)

December 15, 2027

Study Registration Dates

First Submitted

August 16, 2019

First Submitted That Met QC Criteria

August 20, 2019

First Posted (Actual)

August 22, 2019

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SNDX-5613-0700
  • 2020-004104-34 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myeloid Leukemia

Clinical Trials on cobicistat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe